“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”
NewS Archive
Bonum Therapeutics to Present Lead Program at AACR
“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”
Business of Biotech Podcast
IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel
The Bio Report Podcast
Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent